NCT07920861
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Adverse events
Timeframe: through study completion
Cmax
Timeframe: From pre-dosing to 140 days post-dosing
AUCinf
Timeframe: From pre-dosing to 140 days post-dosing
Secondary (9)
AUC
Cmax
Tmax
Vz
CL
Show 4 moreShow less
t1/2
Adverse events
ADA
Nab
Arms and interventions
PART1: Group 1,75mgExperimental
single-dose, SC, HB0017 75 mg or placebo
PART1: Group 2, 150mgExperimental
single-dose, SC, HB0017 150 mg or placebo
PART1: Group 3, 300mgExperimental
single-dose, SC, HB0017 300 mg or placebo
PART2: Group 4, 150mg, domenExperimental
single-dose, SC at domen, HB0017 150 mg
PART2: Group 5, 150mg, upper armsExperimental
single-dose, SC at upper arms, HB0017 150 mg
PART2: Group 6, 150mg, thihgsExperimental
single-dose, SC at thighs, HB0017 150 mg
PART2: Group 7, 300mg, domenExperimental
single-dose, SC at domen, HB0017 300 mg
PART2: Group 8, 300mg, upper armsExperimental
single-dose, SC at upper arms, HB0017 300 mg
PART2: Group 9, 300mg, thighsExperimental
single-dose, SC at thighs, HB0017 300 mg
Biologicals: HB0017 Injection
Other: HB0017 Placebo
Sites
1 site in 1 country
- First People's Hospital of HangzhouHangzhou, Zhejiang, China